The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 trial of OCV-C02, a peptide vaccine for metastatic colorectal cancer patients refractory to all standard chemotherapies.
 
Satoru Iwasa
Honoraria - Lilly Japan; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst)
 
Hiroya Taniguchi
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); MSD Oncology (Inst); Otsuka (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst)
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)
 
Chika Kiryu
Employment - Otsuka
Stock and Other Ownership Interests - Otsuka
 
Ei Leen Liew
Employment - Otsuka
 
Yoshiharu Naka
Employment - Otsuka
Stock and Other Ownership Interests - Otsuka
 
Yuh Sakata
Honoraria - Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Otsuka; Taiho Pharmaceutical